H2S as a Therapeutic Adjuvant Against COVID-19: Why and How? : Shock

Secondary Logo

Journal Logo

Invited Opinion

H2S as a Therapeutic Adjuvant Against COVID-19: Why and How?

Datzmann, Thomas; Merz, Tamara; McCook, Oscar; Szabo, Csaba; Radermacher, Peter

Author Information
SHOCK 56(5):p 865-867, November 2021. | DOI: 10.1097/SHK.0000000000001723
  • Free

Recently, H2S has been proposed as a potential therapy for patients with SARS-CoV-2 (COVID-19) pneumonia (1), and in this context, its effects have been attributed to various mechanisms:

  • 1. It is well established that SARS-CoV-2 enters the cell via docking to the membrane-bound angiotensin-converting enzyme2 (ACE2) after cleavage of one of its surface proteins by the host's transmembrane protease serine 2 (TMPRSS2). In fact, both the severity (2) and extra-pulmonary manifestations (3) of the SARS-CoV-2 disease have been associated with variable ACE2 and/or TMPRSS2 activities. Consequently, H2S-related reduction of their activity could be therapeutically relevant (4).
  • 2. Besides the blockade of virus entry into the cell, H2S may act via inhibition of virus replication as demonstrated in other RNA viruses (5): the slow-releasing H2S donor GYY4137 attenuated alveolar epithelial cell pro-inflammatory cytokine release due to reduced virus replication, while both genetic deletion (6) and pharmacological inhibition (7) of cystathionine-γ-lyase (CSE), one of the major H2S-producing enzymes, exerted the opposite effect.
  • 3. Oxidative stress (8, 9) resulting from glutathione (GSH) deficiency (10) seems to be a key factor for the severity of the SARS-CoV-2 disease. An antioxidant effect of H2S may replenish GSH, thereby producing cytoprotective effects.
  • 4. H2S could attenuate the SARS-CoV-2-related “cytokine storm” due to the downregulation of the production of various pro-inflammatory mediators (11) and/or via the inhibition of leukocyte activation (12).
  • 5. Endothelial dysfunction is a significant part of SARS-CoV-2 disease (13), and H2S donors have been demonstrated to exert significant endothelium-protective effects in various experimental models (14). This point is especially pertinent, because the epidemiology of the SARS-CoV-2 disease clearly suggests a particular role of H2S: the majority of patients needing mechanical ventilation and extra-pulmonary organ support are older and/or suffer from underlying chronic cardiovascular, metabolic, and/or pulmonary comorbidity. All these conditions are well known to be associated with impaired endogenous H2S availability and/or reduced CSE expression (12).
  • 6. In addition, H2S was found to potentiate T-cell activation and regulate Treg-cell-associated immune homeostasis, with the net effect being a stimulation of the immune response (15). Such effects may be beneficial in the context of stimulation of anti-SARS-CoV-2 immune responses.
  • 7. Finally, recently, Renieris et al. (16) demonstrated in this journal that high baseline concentrations of reactive sulfur species and/or their lacking decrease over time were associated with worse outcome of SARS-CoV-2. While the absolute concentrations reported clearly have to be questioned (17), this observation nevertheless suggests investigating exogenous H2S as a therapeutic approach.

It is self-evident that any potential therapeutic approach using H2S donation raises the question of the route of application. Theoretically, two possible strategies could be considered: boosting endogenous H2S formation, i.e., by supplementing upstream substrates and/or cofactors of the H2S-producing enzymes (e.g., taurine, vitamin B6, α-keto-glutarate), or exogenous H2S administration. The latter approach can either make direct use of the H2S molecule itself, i.e., by inhaling gaseous H2S, or use molecules that can “release” H2S (Fig. 1). In this journal, Ali et al. (18) advocate a clinical trial to explore the use of inhaled H2S for the management of SARS-CoV-2-related ARDS. Albeit inhaling gaseous H2S has already been performed in small studies in healthy human volunteers (19), for several reasons, we strongly recommend NOT to use this approach in SARS-CoV-2 patients (20): due to its potential toxicity, its use requires special equipment and personnel for storage and handling, as well as close monitoring of the environmental and delivered concentrations to protect any bystander; it is well established that gaseous H2S is an irritant of the airway mucosa; a direct comparison of inhaled H2S and infusion of the H2S-releasing salt Na2S in murine ventilator-induced lung injury showed that in contrast to the protective effect of infusing Na2S, inhaling H2S dose-dependently had either no or even detrimental effects (21). Injection of the rapidly H2S-“releasing” salts (Na2S, NaHS) results in initially high concentrations that subsequently rapidly disappear, and, in addition, may have adverse properties, e.g., induce pro- rather than anti-inflammatory effects (20). While at least under intensive care unit conditions, this inconvenient of bolus injection could theoretically be overcome by constant i.v., infusion, in clinically relevant large animal models, this approach had beneficial effects only within a narrow dose and time window (22). It is questionable as well, whether the recently developed “slow-releasing” H2S donors, e.g., GYY4137 or the mitochondria-targeted compound AP39, will find their way into clinical practice: despite abundant promising experimental studies both in vitro and in vivo, the available data from fully resuscitated animal models showed either hardly any protective properties or even detrimental side effects (23, 24). Given the above-mentioned pitfalls of inhaling gaseous H2S or infusing Na2S-based i.v. solutions and the uncertainties of the newly developed compounds, interest has focused on the potential use of molecules, which are known sources of H2S and are already recognized drugs for other indications. GSH replenishment can be achieved using its precursor N-acetyl-cysteine (NAC), which, moreover, would also potentially attenuate SARS-CoV-2-related “cytokine storm” (25) as well as allow for ACE2 inhibition (8). However, despite its promising pharmacological profile, in a single-center, double-blind, randomized, placebo-controlled trial in 135 patients, high-dose NAC (∼ 300 mg/kg over 20 h) did not beneficially affect the evolution of severe SARS-CoV-2 (26). Other potential candidates are ammonium-tetrathiomolybdate, which is recognized for the treatment of Wilson's disease, and sodium thiosulfate (Na2S2O3), which is well established for the treatment of cyanide intoxication, cis-platinum overdose, and calciphyllaxis. Ammonium-tetrathiomolybdate (ATTM) showed promising results in rat hemorrhage and cerebral and myocardial ischemia/reperfusion (27). Na2S2O3 not only was organ-protective in both murine endotoxin- and polymicrobial sepsis-induced acute lung injury (28), but, in particular, also improved lung mechanics and gas exchange in a clinically relevant, resuscitated long-term model of hemorrhage-and resuscitation in chronically comorbid swine characterized by coronary arterial CSE deficiency due to underlying ubiquitous atherosclerosis (29). It should be noted, however, that so far neither ATTM nor Na2S2O3 have been investigated in patients with SARS-CoV-2.

Fig. 1:
Pharmacological approaches to strengthen antiviral activity via increased H2S availability in patients suffering from SARS-CoV-2 disease. 3-MST indicates 3-mercaptopyruvate sulfurtransferase; ATTM, ammonium-tetrathiomolybdate; CBS, cystathionine-β-synthase; CSE, cystathionine-γ-lyase; Na2S, sodium sulfide; Na2S2O3, sodium thiosulfate; NaHS, sodium hydrogen sulfide. Adapted from (32).

In conclusion, there is sound evidence that H2S bears the potential as a “defense against COVID-19” (4), in particular since currently there is no effective drug for the treatment of the disease. While inhalation of gaseous H2S cannot be recommended so far, its administration (either via inhalation as aerosols and/or i.v. infusion (30)) using already recognized drugs that are well-established sources of H2S in biological systems, warrants investigation in the clinical setting (31, 32).


1. Citi V, Martelli A, Brancaleone V, Brogi S, Gojo G, Montanaro R, Morales G, Testai L, Calderone V. Anti-inflammatory and antiviral roles of hydrogen sulfide: rationale for considering H2S donors in COVID-19 therapy. Br J Pharmacol 177 (21):4931–4941, 2020.
2. Asselta R, Paraboschi EM, Mantovani A, Duga S. ACE2 and TMPRSS2 variants and expression as candidates to sex and country differences in COVID-19 severity in Italy. Aging (Albany NY) 12 (11):10087–10098, 2020.
3. Dong M, Zhang J, Ma X, Tan J, Chen L, Liu S, Xin Y, Zhuang L. ACE 2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother 131:110678, 2020.
4. Yang G. H2S as a potential defense against COVID-19? Am J Physiol Cell Physiol 319 (2):C244–C249, 2020.
5. Bazhanov N, Escaffre O, Freiberg AN, Garofalo RP, Casola A. Broad-range antiviral activity of hydrogen sulfide against highly pathogenic RNA viruses. Sci Rep 7:41029, 2017.
6. Ivanciuc T, Sbrana E, Ansar M, Bazhanov N, Szabo C, Casola A, Garofalo RP. Hydrogen sulfide is an antiviral and antiinflammatory endogenous gasotransmitter in the airways. Role in respiratory syncytial virus infection. Am J Respir Cell Mol Biol 55 (5):684–696, 2016.
7. Li H, Ma Y, Escaffre O, Ivanciuc T, Komaravelli N, Kelly JP, Coletta C, Szabo C, Rockx B, Garofalo RP, et al. Role of hydrogen sulfide in paramyxovirus infections. J Virol 89 (10):5557–5568, 2015.
8. De Flora S, Balansky R, La Maestra S. Rationale for the use of N-acetylcysteine in both prevention and adjuvant therapy of COVID-19. FASEB J 34(10):13185–13193, 2020.
9. Silvagno F, Vernone A, Pescarmona GP. The Role of Glutathione in Protecting against the Severe Inflammatory Response Triggered by COVID-19. Antioxidants (Basel) 9 (7):624, 2020.
10. Polonikov A. Endogenous deficiency of glutathione as the most likely cause of serious manifestations and death in COVID-19 patients. ACS Infect Dis 6 (7):1558–1562, 2020.
11. Perry MM, Hui CK, Whiteman M, Wood ME, Adcock I, Kirkham P, Michaeloudes C, Chung KF. Hydrogen sulfide inhibits proliferation and release of IL-8 from human airway smooth muscle cells. Am J Respir Cell Mol Biol 45 (4):746–752, 2011.
12. Wang R. Physiological implications of hydrogen sulfide: a whiff exploration that blossomed. Physiol Rev 92 (2):791–896, 2012.
13. Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther 5 (1):293, 2020.
14. Wang R, Szabo C, Ichinose F, Ahmed A, Whiteman M, Papapetropoulos A. The role of H2S bioavailability in endothelial dysfunction. Trends Pharmacol Sci 36 (9):568–578, 2015.
15. Dilek N, Papapetropoulos A, Toliver-Kinsky T, Szabo C. Hydrogen sulfide: an endogenous regulator of the immune system. Pharmacol Res 161:105119, 2020.
16. Renieris G, Katrini K, Damoulari C, Akinosoglou K, Psarrakis C, Kyriakopoulou M, Dimopoulos G, Lada M, Koufargyris P, Giamarellos-Bourboulis EJ. Serum hydrogen sulfide and outcome association in pneumonia by the SARS-CoV-2 coronavirus. Shock 54 (5):633–637, 2020.
17. Radermacher P, Calzia E, McCook O, Wachter U, Szabo C. To the Editor. Shock 55 (1):138–139, 2021.
18. Ali MAM, Saleem MK, Ali NK, Alani MA, Ahmed MM, Sabry SM. Assessment of inhaled hydrogen sulfide in suppressing deterioration in patients with COVID-19. Shock 2021; Online ahead of print.
19. Bhambhani Y, Burnham R, Snydmiller G, MacLean I. Effects of 10-ppm hydrogen sulfide inhalation in exercising men and women. Cardiovascular, metabolic, and biochemical responses. J Occup Environ Med 39 (2):122–129, 1997.
20. Szabo C, Papapetropoulos A. International union of basic and clinical pharamcology. CII: pharmacological modulation of H2S Levels: H2S donors and H2S biosynthesis inhibitors. Pharmacol Rev 69 (4):497–564, 2017.
21. Francis RC, Vaporidi K, Bloch KD, Ichinose F, Zapol WM. Protective and detrimental effects of sodium sulfide and hydrogen sulfide in murine ventilator-induced acute lung injury. Anesthesiology 115 (5):1012–1021, 2011.
22. Asfar P, Calzia E, Radermacher P. Is pharmacological, H2S-induced 'suspended animation’ feasible in the ICU? Crit Care 18 (2):215, 2014.
23. Nussbaum BL, Josef Vogt J, Wachter U, McCook O, Wepler M, Matallo J, Calzia E, Gröger M, Georgieff M, Wood ME, et al. Metabolic, cardiac, and renal effects of the slow hydrogen sulfide-releasing molecule GYY4137 during resuscitated septic shock in swine with pre-existing coronary artery disease. Shock 48 (2):175–184, 2017.
24. Wepler M, Merz T, Wachter U, Vogt JA, Calzia E, Scheuerle A, Möller P, Gröger M, Kress S, Lukaschewski B, et al. The Mitochondria-Targeted H2S-donor ap39 in a murine model of combined hemorrhagic shock and blunt chest trauma. Shock 52 (2):230–239, 2019.
25. Zhou N, Yang X, Huang A, Chen Z. The potential mechanism of N-acetylcysteine in treating COVID-19. Curr Pharm Biotechnol 22 (12):1584–1590, 2021.
26. de Alencar JCG, de Lucena Moreira C, Müller AD, Chaves CE, Fukuhara MA, Silva EA S, Pinto MFS, Bueno VB, Lazar C, Gomez F, et al. Covid Register Group. Double-blind, randomized, placebo-controlled trial with N-acetylcysteine for treatment of severe acute respiratory syndrome caused by COVID-19. Clin Infect Dis 2020; Online ahead of print.
27. Dyson A, Dal-Pizzol F, Sabbatini G, Lach AB, Galfo F, Dos Santos Cardoso J, Pescador Mendonça BP, Hargreaves I, Pinto BB, Bromage DI, et al. Ammonium tetrathiomolybdate following ischemia/reperfusion injury: chemistry, pharmacology, and impact of a new class of sulfide donor in preclinical injury models. PLoS Med 14 (7):e1002310, 2017.
28. Sakaguchi M, Marutani E, Shin HS, Chen W, Hanaoka K, Xian M, Ichinose F. Sodium thiosulfate attenuates acute lung injury in mice. Anesthesiology 121 (6):1248–1257, 2014.
29. Datzmann T, Hoffmann A, McCook O, Merz T, Wachter U, Preuss J, Vettorazzi S, Calzia E, Gröger M, Kohn F, et al. Effects of sodium thiosulfate (Na2S2O3) during resuscitation from hemorrhagic shock in swine with preexisting atherosclerosis. Pharmacol Res 151:104536, 2020.
30. Evgen’ev MB, Frenkel A. Possible application of H2S-producing compounds in therapy of coronavirus (COVID-19) infection and pneumonia. Cell Stress Chaperones 25 (5):713–715, 2020.
31. Merz T, Denoix N, Wepler M, Gäßler H, Messerer DAC, Hartmann C, Datzmann T, Radermacher P, McCook O. H2S in acute lung injury: a therapeutic dead end(?). Intensive Care Med Exp 8: (suppl 1): 33, 2020.
32. Dattilo M. The role of host defences in Covid 19 and treatments thereof. Mol Med 26 (1):90, 2020.
Copyright © 2021 by the Shock Society